Search Results
Your search for ,foR matches 33275 pages
Showing 28801 - 28850Kay Research and Care Center Opens at St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital in Memphis has officially opened the Kay Research and Care Center. The new $198 million center houses the Eric Trump Foundation Surgery and ICU Center, and the Marlo Thomas Center for Global Education and Collaboration. The St. Jude Red Frog Events Proton...
Improving the Quality of Palliative Care in Oncology
Two years ago, ASCO collaborated with the American Academy of Hospice and Palliative Medicine to develop the Virtual Learning Collaborative, a virtual quality improvement program intended to address the complex care needs of patients with advanced cancer and the care quality for all patients with...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...
The Current State of Hematologic Malignancies
Due in part to the refinement of bone marrow transplantation and its many innovations, some leukemias that once were death sentences now have cure rates of up to 90%. As research in transplantation and other promising areas accelerates, we are on the verge of breaking new clinical boundaries in...
MD Anderson Names Patrick Hwu, MD, Head of Cancer Medicine
Patrick Hwu, MD, Chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, has been named Division Head of Cancer Medicine. He will take over from Richard Champlin, MD, who has been acting Division Head on an ad interim basis. Dr. ...
American Association for Cancer Research Inducts 2015 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) has announced 11 new fellows of the AACR Academy. The AACR Academy is an entity that recognizes individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only individuals whose work has had a...
Treating Head and Neck Cancer in 2015
Each year in the United States, about 55,000 people will be diagnosed with head and neck cancer, and of them, about 12,000 will die of the disease. Although advances have been made in the treatment of head and neck cancer, this disease remains persistently problematic, due, in part, to the complex...
Clinically Inappropriate Patient Demands of Oncologists Happen More Infrequently Than Expected
A new study1 conducted at outpatient oncology centers found that only 1% of 5,050 patient-clinician encounters resulted in a clinically inappropriate request, of which very few were complied with by physicians. Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania, and colleagues analyzed...
For Hodgkin Lymphoma Patients, It Ain’t Over
With less than 10,000 patients diagnosed with Hodgkin lymphoma each year and a cure rate of approximately 75% to 80%, drug development for this disease was never a priority for pharmaceutical companies. So when the antibody-drug conjugate brentuximab vedotin (Adcetris) was approved by the U.S. Food ...
PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the programmed cell death protein 1 (PD-1) pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of the PD-1...
MD Anderson Receives $22.3 Million in CPRIT Research Funding
The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). The CPRIT awards will go toward studies in the areas of breast, skin, prostate, pancreas, colon, and lung cancers in adults,...
The Search for Optimal Adjuvant Breast Cancer Chemotherapy: The End of an Era?
Using a complex and innovative study design, Budd and colleagues from the Southwest Oncology Group (SWOG) addressed, in a randomized multicenter trial,1 an issue that has been under evaluation for over 40 years—namely, what are the optimal dose and schedule for adjuvant breast cancer chemotherapy?...
Combination Treatment Every 2 Weeks May Benefit Some Women With High-Risk Early-Stage Breast Cancer
In a phase III trial (SWOG S0221) reported in the Journal of Clinical Oncology, George T. Budd, MD, of Taussig Cancer Center, Cleveland Clinic, and colleagues found no difference in disease-free survival among four different combinations of continuous or every-other-week...
ASCO Collaborates in Launch of Crowd-Sourced Molecular Oncology Tumor Board Series
The ASCO University®, the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) recently announced their collaboration to create the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the...
Highlights From the 2014 Palliative Care in Oncology Symposium
The inaugural 2014 Palliative Care in Oncology Symposium was held October 24 to 25 in Boston. Over 200 abstracts were presented, covering topics such as the integration of palliative care into treatment and the financial hardships facing people living with cancer. The following abstracts were among ...
ASCO Supports HHS Shift Toward Alternative Payment Models
The U.S. Department of Health and Human Services (HHS) has announced its intention to shift Medicare away from the current fee-for-service model and toward a system that pays providers based on the quality—rather than the quantity—of care they provide their patients. The announcement marks the...
Highlights From the 2014 ASCO Quality Care Symposium
The 2014 ASCO Quality Care Symposium was held October 17 to 18 in Boston and featured research on combating disparities, improving end-of-life care, and finding opportunities for cost reduction. These highlights have been adapted from ASCO Quality Care Symposium Daily News (quality.asco.org/dn)....
Expanding the Reach of ASCO’s Educational Efforts
Catherine H. Van Poznak, MD, Associate Professor of Medical Oncology at the University of Michigan, uses the skills she learned as a 2010–2011 participant in ASCO’s Leadership Development Program (LDP) to further the Society’s educational efforts through her service on the Professional Development...
Conquer Cancer Foundation Researcher Spotlight
James D. Murphy, MD, MS, Assistant Professor in the Department of Radiation Medicine at the University of California, San Diego, received a 2012 Conquer Cancer Foundation (CCF) of ASCO Young Investigator Award for his research focusing on access to the delivery of palliative radiation therapy. Dr....
Aged to (Im)Perfection: Age-Related Clonal Hematopoiesis?
Five decades ago, the analysis of metaphase chromosomes in the hematologic malignancies provided our first broad glimpse into the genetic anatomy of a malignant cell. Today, the advent of high-throughput methods such as next-generation sequencing, capable of surveying the entire genome, provides an ...
Clonal Hematopoiesis With Somatic Mutations Increases Risk of Hematologic Cancer, Mortality, and Cardiovascular Disease
In two studies recently reported in The New England Journal of Medicine,1,2 whole-exome sequencing of DNA from peripheral blood cells of individuals unselected for hematologic phenotype showed that clonal hematopoiesis with somatic mutations is increasingly common with increasing age and is...
Jennifer Adair, PhD, Recognized as ‘Outstanding New Investigator’
Jennifer Adair, PhD, of the Fred Hutchinson Cancer Research Center, has been named a 2015 Outstanding New Investigator by the American Society of Gene & Cell Therapy (ASGCT). The award recognizes Dr. Adair’s independent research efforts to understand and improve blood stem cell–based gene...
Determining Why Not All Patients Respond to PD-1 Inhibitors
Recent research1 conducted by Robert H. Pierce, MD, and his colleagues investigating why PD-1 (programmed cell death protein 1) inhibitors result in remarkably durable clinical remissions in some patients with melanoma, whereas others reap a short-term benefit or no benefit at all is showing that...
Crizotinib Crosses Another Finish Line in Lung Cancer
Treatment of anaplastic lymphoma kinase (ALK)–positive lung cancer has been one of the great success stories in oncology in the past decade. First discovered in lung cancer in 2007, ALK rearrangements are found in 3% to 5% of patients and define a distinct molecular subgroup of the disease with...
First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC
In a phase III trial (PROFILE 1014) reported in The New England Journal of Medicine, Benjamin J. Solomon, MB, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in...
Human Reovirus Formulation Gets Orphan Drug Designation in Ovarian and Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of ovarian and pancreatic cancer. The reovirus’s primary mode of activity is to infect and selectively target tumors...
FDA Approves Lenvatinib for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...
FDA Grants Breakthrough Therapy Designation to MPDL3280A for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Genentech’s investigational cancer immunotherapy MPDL3280A for the treatment of PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed during or after platinum-based chemotherapy (and an...
FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a decision on...
FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer
The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy....
Lenvatinib in Advanced Radioiodine-Refractory Differentiated Thyroid Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 13, 2015, lenvatinib (Lenvima) was approved for the...
Nivolumab in Previously Treated Metastatic Renal Cell Cancer
The approval of multiple inhibitors of either the VEGF or mTOR pathway provided an incremental advance in the treatment of metastatic clear cell renal cancer. However, the agents have several important limitations: For example, the optimal clinical effect appears to be dependent on chronic...
Nivolumab Shows Activity in Previously Treated Metastatic Renal Cell Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the programmed cell death protein-1 (PD-1) immune checkpoint inhibitor antibody nivolumab (Opdivo) was associated with...
Expert Point of View: Richard Little, MD
The National Cancer Institute (NCI) sees a real need for additional study of treatment options for human immunodeficiency virus (HIV)-infected patients with malignancies. The results of this trial make us confident that exclusion from autologous transplant studies on the basis of HIV serostatus is...
HIV-Related Lymphoma Can Be Safely Treated With Transplant
Human immunodeficiency virus (HIV)-positive patients with relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplantation, according to results of a phase II multicenter trial presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in...
From ASH 2014: What’s New in the Myeloma Treatment Arsenal?
At the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, attendance at many multiple myeloma sessions outnumbered the room size, as data from studies of novel agents, such as the monoclonal antibodies, and from key trials, such as ASPIRE, drew crowds. The ASCO Post covered...
PI3K Inhibition in Hormone Receptor–Positive Breast Cancer ‘Not Ready for Prime Time’
Interest is high in studying the PI3K pathway in hormone receptor–positive breast cancer, but it is not clear which of the PI3K inhibitors under development—if any—will be a “home run.” The phase II FERGI study, reported at the 2014 San Antonio Breast Cancer Symposium, failed to meet its primary...
Expert Point of View: Hagan Kennecke, MD, Pamela L. Kunz, MD, and George Fisher, MD, PhD
Hagan Kennecke, MD, Associate Professor, University of British Columbia at the British Columbia Cancer Agency, said in an interview, “It was important to see the detailed subgroup analysis for pancreatic neuroendocrine tumors, because that is a major patient population we treat, and it was not...
Lanreotide Evaluated in Pancreatic Neuroendocrine Subgroup
The somatostatin analog lanreotide (Somatuline) depot extended the time to disease progression in patients with pancreatic neuroendocrine tumors, in a planned subgroup analysis of the CLARINET trial, Alexandria T. Phan, MD, of The Houston Methodist Hospital in Texas, reported at the 2015...
Expert Point of View: Laura A. Dawson, MD
Session moderator Laura A. Dawson, MD, of the University of Toronto, commented on this study by Dr. Ross and colleagues for The ASCO Post: “Moving forward, I think we need to change the way we make treatment decisions, no question. Treatment based on profiling is the way of the future. Dr. Ross’...
Targeting Biliary Tract Cancers Through Genomic Profiling
Biliary tract cancers are challenging, but a large genomic profiling study has identified potentially clinically relevant genomic alterations in up to two-thirds of patients.1 “The diverse landscape of clinically relevant genomic alterations in biliary tract cancers can serve as targets for...
Inhibiting the MET Pathway in Gastroesophageal Cancer: Hits and Misses
The MET pathway appears to be important in gastroesophageal cancers, but response to a targeted agent may depend on the class of drugs. A robust response to the novel small-molecule MET inhibitor AMG 337 was observed, but a monoclonal antibody targeting MET fell flat, in studies reported at the...
New Data Reported in Colorectal, Gastric, and Pancreatic Cancers
The 2015 Gastrointestinal Cancers Symposium, held January 15–17 in San Francisco, attracted almost 4,000 attendees, who heard or viewed data from nearly 800 scientific abstracts and lectures. Here are our summaries of some of the many important developments from the meeting. Bevacizumab Plus...
Addressing the Global Cancer Burden
Since 1990, the annual global death toll from cancer has risen about 40%, and that number is projected to increase from the current level of approximately 8 million cancer deaths per year to more than 13 million by 2030. The poorer, resource-challenged regions of the world will suffer a...
Big Data and the Promise of Precision Medicine in Cancer
Precision medicine—and its promise to revolutionize how we understand disease and care for our patients—is a concept that oncology has understood and embraced for well over a decade. But millions of Americans recently heard about the concept for the first time when President Obama announced a...
Active Surveillance in Intermediate-Risk Prostate Cancer Called Into Question
A study presented at the 2015 Genitourinary Cancers Symposium calls into question the use of active surveillance in patients with intermediate-risk prostate cancer. Patients with intermediate-risk prostate cancer managed with active surveillance had almost a four times higher risk of prostate...
Key Evidence Gaps and Research Priorities Should Be Addressed So Physicians Can Identify Patients Most Likely to Benefit From Opioids
Key evidence gaps and research priorities must be addressed “so that physicians can recognize patients for whom opioids are most appropriate and use optimal regimens for these patients,” according to the National Institutes of Health (NIH) Pathways to Prevention Workshop final report on the role of ...
Nearly Half of Women Taking Tamoxifen for Primary Prevention Discontinue Its Use Before 5 Years
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued its use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister diagnosed with breast cancer but did not have breast cancer themselves. Eligible...
Selenium Supplements After Diagnosis of Nonmetastatic Prostate Cancer May Raise Prostate Cancer Mortality Risk
“Selenium supplementation of 140 or more μg/d after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality,” according to a prospective study following 4,459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-up Study...
